Uro-EDICII: Risk and Progression of Urologic Complications in Type 1- Diabetes

Uro-EDICII:1 型糖尿病泌尿系统并发症的风险和进展

基本信息

  • 批准号:
    8144537
  • 负责人:
  • 金额:
    $ 6.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-25 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Urinary incontinence, lower urinary tract symptoms and sexual dysfunction are common health problems that reduce quality of life and markedly increase in prevalence and incidence with advancing age. Earlier onset and increased severity of those conditions among men and women with diabetes result in costly and debilitating symptoms. However, data to define incidence, associated factors and interventions to reduce the risk of developing these complications among men and women with type 1 diabetes (T1D) are limited. We have assembled a multidisciplinary team to implement an ancillary study to the Epidemiology of Diabetes Intervention and Complication (EDIC) study, a major ongoing NIDDK research study. The collection of additional survey information from EDIC participants, combined with existing and new biological specimens, will repurpose this important study to measure the new onset of urological symptoms during an important window of time in which the frequency of urological complications is accelerating. Our hypothesis is that urological complications of diabetes impair quality of life (QOL) and that diabetic and systemic factors can be identified that predict men and women at risk for these complications. Our specific aims are to 1) measure the onset and progression of urinary incontinence (UI), lower urinary tract symptom severity (LUTS), and sexual dysfunction (SDF) in men and women with T1D and determine the influence of glycemic therapy and diabetes severity on these complications; 2) determine the influence of low testosterone levels and prostate growth on the associations between glycemic therapy, diabetes severity and the complications of LUTS and SDF in men and 3) measure the impact of the onset and progression of urologic complication on health related QOL I men and women with T1D. The timing of this study is critical in order to capture the upswing in incidence of urological complications as the EDIC cohort reaches 50 years of age. The completion of these aims will provide comprehensive insight into the association between urologic complication and T1D and the impact of these symptoms on QOL. Predictive and protective factors will be identified that map out strategies for intervention and prevention studies. Findings from this proposal may also reveal important relationships between diabetic factors and ageing, bladder and prostate biology, and provide a data repository for biomarker discovery and genome wide association studies. Public Health Relevance: (adapted from the application) The proposed study is likely to offer an opportunity to complete important investigations on urological complications of type 1diabetes by repurposing the DCCT/EDIC parent study and its established cohorts. The collection of additional survey information from recruited study participants is likely to give a one-time chance to capture incident urological complications and the impact of these conditions on quality of life. The precise data from this study will be important to educate patients and their families, help develop biomarkers of urological complications and provide refined phenotypes for genetic susceptibility studies.
描述(由申请人提供): 尿失禁、下尿路症状和性功能障碍是降低生活质量的常见健康问题,随着年龄的增长,患病率和发病率显著增加。男性和女性糖尿病患者发病更早,病情更严重,会导致代价高昂且使人虚弱的症状。然而,定义发病率、相关因素和干预措施以降低1型糖尿病(T1D)男性和女性发生这些并发症的风险的数据有限。我们已经组建了一个多学科团队来实施糖尿病干预和并发症流行病学(EDIC)研究的辅助研究,这是一项正在进行的主要NIDDK研究。从EDIC参与者那里收集更多的调查信息,结合现有的和新的生物标本,将改变这项重要研究的目的,以衡量在泌尿系统并发症频率加快的重要窗口期间新出现的泌尿症状。我们的假设是,糖尿病的泌尿系统并发症损害了生活质量(QOL),可以确定糖尿病和全身因素可以预测男性和女性有这些并发症的风险。我们的具体目标是:1)测量T1D男性和女性尿失禁(UI)、下尿路症状严重程度(LUTS)和性功能障碍(SDF)的发生和发展,并确定血糖治疗和糖尿病严重程度对这些并发症的影响;2)确定低睾酮水平和前列腺生长对男性血糖治疗、糖尿病严重程度和LUTS和SDF并发症之间关系的影响;3)测量泌尿系统并发症的发生和进展对患有T1D的男性和女性健康相关QOL I的影响。这项研究的时机对于捕捉随着EDIC队列达到50岁时泌尿系并发症发生率的上升是至关重要的。这些目标的完成将提供对泌尿系并发症和T1D之间的联系以及这些症状对生活质量的影响的全面洞察。将确定预测性和保护性因素,为干预和预防研究制定战略。这一建议的结果还可能揭示糖尿病因素与衰老、膀胱和前列腺生物学之间的重要关系,并为生物标记物发现和全基因组关联研究提供数据存储库。 公共卫生相关性:(改编自申请)拟议的研究可能提供一个机会,通过重新调整DCCT/EDIC母公司研究及其已建立的队列,完成对1型糖尿病泌尿系统并发症的重要调查。从招募的研究参与者那里收集额外的调查信息可能会给我们一个一次性的机会来捕捉发生的泌尿系统并发症以及这些情况对生活质量的影响。这项研究的准确数据将对教育患者及其家人、帮助开发泌尿系统并发症的生物标记物以及为遗传易感性研究提供精确的表型具有重要意义。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ARUNA V SARMA其他文献

ARUNA V SARMA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ARUNA V SARMA', 18)}}的其他基金

Professional Development Core
专业发展核心
  • 批准号:
    10506492
  • 财政年份:
    2022
  • 资助金额:
    $ 6.2万
  • 项目类别:
Professional Development Core
专业发展核心
  • 批准号:
    10705181
  • 财政年份:
    2022
  • 资助金额:
    $ 6.2万
  • 项目类别:
UroEDIC Bladder: Bladder Dysfunction in Type 1 Diabetes
UroEDIC 膀胱:1 型糖尿病的膀胱功能障碍
  • 批准号:
    10406303
  • 财政年份:
    2021
  • 资助金额:
    $ 6.2万
  • 项目类别:
UroEDIC Bladder: Bladder Dysfunction in Type 1 Diabetes
UroEDIC 膀胱:1 型糖尿病的膀胱功能障碍
  • 批准号:
    10606540
  • 财政年份:
    2021
  • 资助金额:
    $ 6.2万
  • 项目类别:
UroEDIC Bladder: Bladder Dysfunction in Type 1 Diabetes
UroEDIC 膀胱:1 型糖尿病的膀胱功能障碍
  • 批准号:
    10205344
  • 财政年份:
    2021
  • 资助金额:
    $ 6.2万
  • 项目类别:
Uro-EDICII: Risk and Progression of Urologic Complications in Type 1- Diabetes
Uro-EDICII:1 型糖尿病泌尿系统并发症的风险和进展
  • 批准号:
    7938939
  • 财政年份:
    2009
  • 资助金额:
    $ 6.2万
  • 项目类别:
Uro-EDICII: Risk and Progression of Urologic Complications in Type 1- Diabetes
Uro-EDICII:1 型糖尿病泌尿系统并发症的风险和进展
  • 批准号:
    8305070
  • 财政年份:
    2009
  • 资助金额:
    $ 6.2万
  • 项目类别:
Uro-EDICII: Risk and Progression of Urologic Complications in Type 1- Diabetes
Uro-EDICII:1 型糖尿病泌尿系统并发症的风险和进展
  • 批准号:
    7687221
  • 财政年份:
    2009
  • 资助金额:
    $ 6.2万
  • 项目类别:
Uro-EDICII: Risk and Progression of Urologic Complications in Type 1- Diabetes
Uro-EDICII:1 型糖尿病泌尿系统并发症的风险和进展
  • 批准号:
    8515391
  • 财政年份:
    2009
  • 资助金额:
    $ 6.2万
  • 项目类别:
Uro-EDICII: Risk and Progression of Urologic Complications in Type 1- Diabetes
Uro-EDICII:1 型糖尿病泌尿系统并发症的风险和进展
  • 批准号:
    8125097
  • 财政年份:
    2009
  • 资助金额:
    $ 6.2万
  • 项目类别:

相似海外基金

Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8306217
  • 财政年份:
    2008
  • 资助金额:
    $ 6.2万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7530462
  • 财政年份:
    2008
  • 资助金额:
    $ 6.2万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    8134266
  • 财政年份:
    2008
  • 资助金额:
    $ 6.2万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7904815
  • 财政年份:
    2008
  • 资助金额:
    $ 6.2万
  • 项目类别:
Age factors, mutations, and chemical suppressors of acute myelogenous leukemia
急性髓性白血病的年龄因素、突变和化学抑制剂
  • 批准号:
    7659629
  • 财政年份:
    2008
  • 资助金额:
    $ 6.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了